title: PEP trial. Pulmonary Embolism Prevention.
authors.forename: I
authors.initials: I
authors.lastname: Mahé
authors.forename: J F
authors.initials: JF
authors.lastname: Bergmann
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: C
authors.initials: C
authors.lastname: Caulin
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006620:Hip Fractures / Q000601:surgery; D006801:Humans; D015201:Meta-Analysis as Topic; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000209:etiology; D011655:Pulmonary Embolism / Q000517:prevention & control*; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control; D020246:Venous Thrombosis / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin